The role of B cells and autoantibodies in neuropsychiatric lupus.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Autoimmunity Reviews

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.autrev.2016.07.009PMID 27389531PMCID PMC4982790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice.

  2016cited by this paper
• Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4

  2016cited by this paper
• Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE.

  2016cited by this paper
• A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus.

  2016cited by this paper
• B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus

  2016cited by this paper
• TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.

  2015cited by this paper
• B Cell–Specific MHC Class II Deletion Reveals Multiple Nonredundant Roles for B Cell Antigen Presentation in Murine Lupus

  2015cited by this paper
• Neuropsychiatric lupus: a mosaic of clinical presentations

  2015cited by this paper
• Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice

  2015cited by this paper
• Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort.

  2015cited by this paper
• AB0528 Efficacy and Safety of Rituximab in the Treatment of Neuropsychiatric Systemic Lupus Erythematosus During Long-Term Follow-Up

  2015cited by this paper
• Biomarkers for CNS involvement in pediatric lupus.

  2015cited by this paper
• Biomarkers for kidney involvement in pediatric lupus.

  2015cited by this paper
• Diagnosis and management of neuropsychiatric SLE

  2014influential reference
• Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

  2014cited by this paper
• Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review

  2014influential reference
• Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis.

  2014cited by this paper
• Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model.

  2014cited by this paper
• [Anti-NMDA receptor antibody in systemic lupus erythematosus].

  2013cited by this paper
• Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

  2013cited by this paper
• Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway

  2013cited by this paper
• The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies.

  2012cited by this paper
• Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

  2012cited by this paper
• Aspects of CNS lupus: mouse models of anti-NMDA receptor antibody mediated reactivity.

  2012influential reference
• Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

  2012cited by this paper
• Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study

  2012cited by this paper
• Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

  2011cited by this paper
• The MRL/lpr Mouse Strain as a Model for Neuropsychiatric Systemic Lupus Erythematosus

  2011influential reference
• Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence.

  2011cited by this paper
• Murine Models of Systemic Lupus Erythematosus

  2011cited by this paper
• Manifestations of systemic lupus erythematosus.

  2011cited by this paper
• A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

  2011cited by this paper
• Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

  2010cited by this paper
• Hippocampal NMDA receptors and anxiety: At the interface between cognition and emotion

  2010cited by this paper
• Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms

  2010cited by this paper
• Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice.

  2010cited by this paper
• Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus.

  2010influential reference
• Depression is an early disease manifestation in lupus-prone MRL/lpr mice.

  2009influential reference
• Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

  2009cited by this paper
• Cytokine, sickness behavior, and depression.

  2009cited by this paper
• Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis

  2008cited by this paper
• Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms

  2008cited by this paper
• Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system.

  2007cited by this paper
• Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis

  2007influential reference
• Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations

  2007cited by this paper
• Depletion of B Cells in Murine Lupus: Efficacy and Resistance1

  2007cited by this paper
• Human lupus autoantibodies against NMDA receptors mediate cognitive impairment

  2006cited by this paper
• Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

  2006cited by this paper
• Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.

  2006cited by this paper
• Cytokine, sickness behavior, and depression.

  2006influential reference
• Effects of systemic lupus erythematosus on spatial cognition and cerebral regional metabolic reactivity in BxSB lupus-prone mice.

  2005cited by this paper
• Anti-ribosomal P protein antibodies

  2005cited by this paper
• Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice.

  2003cited by this paper
• The blood-brain barrier in systemic lupus erythematosus

  2003cited by this paper
• Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer

  2003cited by this paper
• B and T cells in the brains of autoimmune mice.

  2002influential reference
• Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.

  2002influential reference
• Immunoglobulin binding to brain in autoimmune mice.

  2001cited by this paper
• Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis.

  2001cited by this paper
• Tumour necrosis factor-α causes an increase in blood-brain barrier permeability during sepsis

  2001cited by this paper
• The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

  1999cited by this paper
• The central and multiple roles of B cells in lupus pathogenesis

  1999influential reference
• B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.

  1999cited by this paper
• Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally.

  1996cited by this paper
• Evaluation of memory, learning ability, and clinical neurologic function in pathogen-free mice with systemic lupus erythematosus.

  1994cited by this paper
• Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus.

  1993cited by this paper
• Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci

  1992cited by this paper
• Brain pathology in systemic lupus erythematosus.

  1992cited by this paper
• The incidence and prognosis of central nervous system disease in systemic lupus erythematosus.

  1992cited by this paper
• Brain abnormalities in immune defective mice.

  1990cited by this paper
• Association between lupus psychosis and anti-ribosomal P protein antibodies.

  1987cited by this paper
• Murine models of systemic lupus erythematosus.

  1985cited by this paper
• Neuropathological features of a lupus‐like disorder in autoimmune mice

  1983cited by this paper
• A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation.

  1979cited by this paper
• The choroid plexus in CNS involvement of systemic lupus erythematosus.

  1975cited by this paper
• [Erythematosus].

  1971cited by this paper

• Intrathecal injection of rituximab inhibits microglial M1 polarisation to alleviate neuropsychiatric SLE symptoms via the cAMP/PKA/CREB signalling pathway

  2026cites this paper
• Depression-like behavior is associated with changes in the meningeal lymphatic vasculature and meningeal B cells in a murine lupus model.

  2025cites this paper
• A cross-sectional study on white matter hyperitensity in patients at the initial diagnosis of neuropsychiatric SLE: Correlation with Clinical and Laboratory Findings

  2025cites this paper
• Case Report: A patient presenting primarily with psychosis of NPSLE treated with telitacicept, corticosteroids, and immunosuppressants

  2025cites this paper
• Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus

  2025cites this paper
• Organ-based characterization of B cells in patients with systemic lupus erythematosus

  2025cites this paper
• Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study

  2025cites this paper
• Neutrophil extracellular traps and neuropsychiatric lupus: Signaling pathways involved in NET formation and mechanisms affecting the central nervous system.

  2025cites this paper
• Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus

  2024cites this paper
• Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus.

  2024cites this paper
• Examination of the shared genetic architecture between multiple sclerosis and systemic lupus erythematosus facilitates discovery of novel lupus risk loci

  2024cites this paper
• Pristane induced lupus mice as a model for neuropsychiatric lupus (NPSLE)

  2023cites this paper
• Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations

  2022cites this paper
• The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement

  2022cites this paper
• Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study

  2022cites this paper
• Aptamer‐Based Screen of Neuropsychiatric Lupus Cerebrospinal Fluid Reveals Potential Biomarkers That Overlap With the Choroid Plexus Transcriptome

  2022cites this paper
• Blood–brain barrier disruption in atrial fibrillation: a potential contributor to the increased risk of dementia and worsening of stroke outcomes?

  2021influential citation
• Clinical efficacy of belimumab in patients with systemic lupus erythematosus and headache. A report of two cases.

  2021cites this paper
• Calcium-Dependent Translocation of S100B Is Facilitated by Neurocalcin Delta

  2021cites this paper
• Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.

  2020cites this paper
• Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review

  2020cites this paper
• Early and Short-Term Interventions in the Gut Microbiota Affects Lupus Severity, Progression, and Treatment in MRL/lpr Mice

  2020cites this paper
• Comparative proteomics analysis of plasma protein in patients with neuropsychiatric systemic lupus erythematosus

  2020cites this paper
• Astrocytic S100B, Blood-Brain Barrier and Neurodegenerative Diseases

  2020cites this paper
• Lupus animal models and neuropsychiatric implications

  2020cites this paper
• Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis

  2020cites this paper
• B-cells and schizophrenia: a promising link or a finding lost in translation?

  2019cites this paper
• Anticuerpos asociados al lupus neuropsiquiátrico: rol fisiopatológico, prevalencia y utilidad diagnóstica

  2019cites this paper
• Leptin: an unappreciated key player in SLE

  2019cites this paper
• Update on the pathogenesis of central nervous system lupus.

  2019influential citation
• Antibodies associated with neuropsychiatric lupus: Pathophysiological role, prevalence and diagnostic usefulness

  2019cites this paper
• Management of Psychosis in Neuropsychiatric Lupus

  2019cites this paper
• Protein glycation: An old villain is shedding secrets.

  2019cites this paper
• Systemic lupus erythematosus: nothing stale her infinite variety

  2018cites this paper
• Highly selective inhibition of Bruton’s tyrosine kinase attenuates skin and brain disease in murine lupus

  2018cites this paper
• Psycho-rheumatic Integration in Systemic Lupus Erythematosus: An Insight into Antibodies Causing Neuropsychiatric Changes

  2018cites this paper
• Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.

  2018cites this paper
• The SLE-key test serological signature: new insights into the course of lupus

  2018cites this paper
• Hello from the Other Side: How Autoantibodies Circumvent the Blood–Brain Barrier in Autoimmune Encephalitis

  2017cites this paper
• International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.

  2017cites this paper
• Autophagy in neuroinflammatory diseases.

  2017cites this paper
• Autoimmunity in 2016

  2017cites this paper